

## **Immunomodulating nanomedicines – from bench to the bedside**

Prof. Dr. Oya Tagit

School of Life Sciences FHNW, Institute for Chemistry and Bioanalytics,  
Hofackerstrasse 30, 4132 Muttenz, Switzerland  
*oya.tagit@fhnw.ch*

Nanomedicines based on poly(lactic-co-glycolic acid) (PLGA) carriers offer tremendous opportunities for biomedical research. Although several PLGA-based systems have already been approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), and are widely used in the clinics for the treatment or diagnosis of diseases, no PLGA nanomedicine formulation is currently available on the global market. One of the most impeding barriers is the development of a manufacturing technique that allows for the transfer of nanomedicine production from the laboratory to an industrial scale with proper characterization and quality control methods. This talk will give an overview of the development and scale-up manufacturing of PLGA-based nanomedicines for cancer immunotherapy.